Abstract LB520: A pharmacodynamic platform using liquid biopsy to support dose selection for the ATR inhibitor ART0380 (IACS-030380)
Manish R. Patel(Sarah Cannon), Melissa M. Johnson(Sarah Cannon), Sarah V. Holt(Pharma Nord (United Kingdom)), Marina Roy Luzarraga, Jayesh B. Majithiya, Kathleen N. Moore(University of Oklahoma Medical Center), Desirèe Piscitello, Helen Millward
Cited by 3
Related Papers
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
|New England Journal of Medicine|2018|2.9k
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533